BTS 74 398
monoamine reuptake inhibitor
Also Known As:
1-(1-(3,4-dichlorophenyl)cyclobutyl)-2-(3-diaminethylaminopropylthio)ethanone monocitrate
Networked: 2
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Experts
Related Diseases
| 1. | Dyskinesias (Dyskinesia)
01/01/2005
- " However, it is not known whether BTS 74 398 primes the basal ganglia for dyskinesia induction. " 01/01/2005
- " The lack of such changes following repeated BTS 74 398 treatment suggests that it may be an effective antiparkinsonian therapy that is unlikely to produce involuntary movements." 01/01/2005
- " Furthermore, striatal DeltaFosB immunoreactivity, shown to correlate with dyskinesia induction, was increased by L-dopa but was unaffected by repeated BTS 74 398 administration. " 01/01/2005
- " In L-dopa-treated rats, orolingual, locomotive, forelimb and axial abnormal movements developed whereas BTS 74 398 produced only locomotion with a side bias but no other abnormal movements. " 01/01/2005
- " BTS 74 398 (1-[1-(3,4-dichlorophenyl)cyclobutyl]-2-(3-diaminethylaminopropylthio)ethanone monocitrate) is a monoamine reuptake inhibitor that reverses motor deficits in MPTP-treated (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) common marmosets without provoking established dyskinesia. "
|
|
Related Drugs and Biologics
Related Therapies and Procedures